Finance

Lists
NVS:NYSE
Novartis AG
$ 143.75
+0.45%
(+0.64) 1D
10-р сарын 9, 16:00:07 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NVS...
Open
$ 142.92
High
$ 143.96
Low
$ 142.80
Mkt. cap
288.81Т
Avg. vol.
2.36 сая
Volume
0.00
Dividend
3.30%
Quarterly dividend
$ 1.19
Ex-dividend date
2026 оны 3-р сарын 10
P/E ratio
21.71
52-wk high
$ 170.46
52-wk low
$ 121.57
EPS
$ 6.62
Beta
0.39
Shares outstanding
2.03 тэрбум
No. of employees
75 мян
Open
$ 142.92
High
$ 143.96
Low
$ 142.80
Mkt. cap
288.81Т
Avg. vol.
2.36 сая
Volume
0.00
Dividend
3.30%
Quarterly dividend
$ 1.19
Ex-dividend date
2026 оны 3-р сарын 10
P/E ratio
21.71
52-wk high
$ 170.46
52-wk low
$ 121.57
EPS
$ 6.62
Beta
0.39
Shares outstanding
2.03 тэрбум
No. of employees
75 мян
News stories
From web sources and news partners
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis AG
CEOVasant Narasimhan
Employees75.3 мян
Founded1996 оны 3-р сарын 7
HeadquartersБазель хот, Basel City, Швейцари
SectorPharmaceutical industry
Analyst ratings
Based on 7 analysts giving stock ratings to NVS in the past 3 months
Buy
Buy
3
Hold
3
Sell
1
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for NVS in the last 3 months.
Highest
Current $ 143.75
$ 180.00 (+25.22%)
Average
$ 154.67 (+7.60%)
Lowest
$ 136.00 (-5.39%)
Analyst
Recommendation
Action
Price target
Projected
Date
Thibault Boutherin
Morgan Stanley
Buy
Maintained
$ 156.00
+8.5%
10/06/2026
Sachin Jain
Bank of America Securities
Buy
Maintained
-
-
10/05/2026
Rajesh Kumar
HSBC
Hold
Upgraded
$ 136.00
-5.4%
09/10/2026
Steve Scala
TD Cowen
Hold
Maintained
$ 180.00
+25.2%
09/08/2026
Kerry Holford
Berenberg Bank
Hold
Maintained
$ 147.00
+2.3%
07/27/2026
Jasper Hellweg
Argus Research
Buy
Maintained
$ 170.00
+18.3%
07/24/2026
Unknown Analyst
Goldman Sachs
Sell
Maintained
$ 139.00
-3.3%
07/22/2026
Justin Smith
Bernstein
Hold
Initiated
-
-
03/19/2026
David Toung
Argus Research
Buy
Upgraded
$ 180.00
+25.2%
03/11/2026
Last report
2026 оны 7-р сарын 21
Fiscal period
Q2 2026
$ 2.41 / $ 2.15
+12.21%beat
Revenue / Est. (USD)
14.95 тэрбум / 14.06 тэрбум
+6.36%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
14.36 тэрбум
13.86 тэрбум
13.52 тэрбум
14.95 тэрбум
Cost of goods sold
3.54 тэрбум
3.54 тэрбум
3.44 тэрбум
3.68 тэрбум
Cost of revenue
3.54 тэрбум
3.54 тэрбум
3.44 тэрбум
3.68 тэрбум
Research and development expenses
2.86 тэрбум
2.84 тэрбум
2.78 тэрбум
2.74 тэрбум
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.30 тэрбум
3.44 тэрбум
3.14 тэрбум
3.23 тэрбум
Operating expense
6.24 тэрбум
6.46 тэрбум
5.96 тэрбум
6.10 тэрбум
Total operating expenses
9.77 тэрбум
10.00 тэрбум
9.40 тэрбум
9.78 тэрбум
Operating income
4.58 тэрбум
3.86 тэрбум
4.12 тэрбум
5.18 тэрбум
Other non operating income
-7.00 сая
-130.00 сая
4.00 сая
19.00 сая
EBT including unusual items
4.20 тэрбум
3.22 тэрбум
3.84 тэрбум
4.27 тэрбум
EBT excluding unusual items
4.29 тэрбум
3.49 тэрбум
3.78 тэрбум
4.73 тэрбум
Income tax expense
266.00 сая
814.00 сая
683.00 сая
1.01 тэрбум
Effective tax rate
6.34%
25.30%
17.79%
23.71%
Other operating expenses
70.00 сая
190.00 сая
42.00 сая
127.00 сая
Net income
3.93 тэрбум
2.41 тэрбум
3.16 тэрбум
3.26 тэрбум
Net profit margin
27.36%
17.38%
23.34%
21.83%
Earnings per share
2.25
2.03
1.99
2.41
Interest and investment income
-
373.00 сая
-
-
Interest expense
-281.00 сая
-304.00 сая
-343.00 сая
-462.00 сая
Net interest expenses
-281.00 сая
69.00 сая
-343.00 сая
-462.00 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
5.78 тэрбум
4.96 тэрбум
5.24 тэрбум
6.30 тэрбум
Gain or loss from assets sale
81.00 сая
80.00 сая
-159.00 сая
-247.00 сая
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google аппс